Pre-made Tezepelumab benchmark antibody ( Whole mAb, anti-TSLP therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-567

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-567 Category Tag

Product Details

Pre-Made Tezepelumab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tezepelumab (INN; development codes MEDI9929 and AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis. It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.

Products Name (INN Index)

Pre-Made Tezepelumab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody

INN Name

Tezepelumab

Target

TSLP

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG2

VD LC

Lambda

Highest_Clin_Trial (Jan '20)

Preregistration

Est. Status

Active

100% SI Structure

5j13:CB

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2015

Companies

Amgen,AstraZeneca,Bispebjerg Hospital,Lund University,MedImmune,University of Copenhagen,University of Newcastle in Australia

Conditions Approved

NA

Conditions Active

Asthma,Atopic dermatitis,Rhinosinusitis,Chronic obstructive pulmonary disease

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

TSLP

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide